Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326481 · ClinicalTrials.gov registry record · Phase 1
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT01326481 is a Phase 1 study of Metastatic Breast Cancer that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 19 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01326481, a Phase 1 study of Metastatic Breast Cancer, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG TRC105
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326481
The ClinicalTrials.gov registry entry for NCT01326481 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT01326481 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, New York.
Frequently Asked Questions
What is clinical trial NCT01326481 about?
NCT01326481 is a clinical study titled "Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer". The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.
What is the current status of trial NCT01326481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2011-06. Estimated completion is 2014-12.
What conditions does trial NCT01326481 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT01326481?
The interventions under investigation include: Capecitabine (DRUG), TRC105 (DRUG).
Who is sponsoring clinical trial NCT01326481?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01326481 being conducted?
This trial has 2 study locations across Alabama, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.